Treatment with sotrovimab for SARS-CoV-2 infection in a cohort of high-risk kidney transplant recipients

BACKGROUND: Sotrovimab is a neutralizing monoclonal antibody (mAb) that seems to remain active against recent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants. The evidence on its use in kidney transplant (KT) recipients, however, is limited. METHODS: We performed a multicenter,...

Descripción completa

Detalles Bibliográficos
Autores principales: Villanego, Florentino, Mazuecos, Auxiliadora, Cubillo, Beatriz, Merino, M José, Poveda, Inmaculada, Saura, Isabel M, Segurado, Óscar, Cruzado, Leónidas, Eady, Myriam, Zárraga, Sofía, Aladrén, M José, Cabello, Sheila, López, Verónica, González, Esther, Lorenzo, Inmaculada, Espí-Reig, Jordi, Fernández, Constantino, Osma, July, Ruiz-Fuentes, M Carmen, Toapanta, Néstor, Franco, Antonio, Burballa, Carla C, Muñoz, Miguel A, Crespo, Marta, Pascual, Julio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9384612/
https://www.ncbi.nlm.nih.gov/pubmed/36147706
http://dx.doi.org/10.1093/ckj/sfac177

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9384612/
https://www.ncbi.nlm.nih.gov/pubmed/36147706
http://dx.doi.org/10.1093/ckj/sfac177

Ejemplares similares